Would you offer Durvalumab as consolidation therapy to a patient with stage III NSCLC but had local recurrence treated with definitive SBRT?

This very relevant and highly challenging question brings to mind Osler’s quote: "Medicine is a science of uncertainty and an art in probability". How do we apply the data that we have to the individual patient in front of us needing our best counsel? How do we apply the now more mature (see prior...